Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Ryan Specialty Holdings Appoints Keogh and Mulshine as Co-Presidents

Ryan Specialty Holdings, Inc. (NYSE: RYAN) has announced the appointment of Steve Keogh and Brendan Mulshine as co-presidents of the company. This change comes as Jeremiah Bickham transitions from his position as president to serve as a strategic advisor through the end of the year.

Steve Keogh, who previously held the role of chief operating officer, and Brendan Mulshine, who served as chief revenue officer, will report to Chief Executive Officer Tim Turner. Both Keogh and Mulshine bring over 30 years of insurance industry experience to their new roles.

Keogh, who joined Ryan Specialty in May 2025, has a background that includes executive roles at Aon, including president of commercial risk solutions and president of U.S. commercial risk & health solutions. Mulshine, on the other hand, has been with Ryan Specialty since 2012 and has previously held leadership roles at Aon over an 18-year period.

In the wake of these changes, Pat Ryan, the founder and executive chairman of Ryan Specialty, expressed confidence in the appointments, highlighting the executives' contributions and the company's deep roster of talent. CEO Tim Turner also expressed optimism about working closely with Keogh and Mulshine to maintain the momentum the company has achieved.

The departure of Jeremiah Bickham after nearly 14 years of service at Ryan Specialty was also acknowledged, with expressions of gratitude for his contributions and well-wishes for his future endeavors.

Founded in 2010, Ryan Specialty is a leading international specialty insurance firm that provides distribution, underwriting, product development, administration, and risk management services. The company's mission is to offer industry-leading innovative specialty insurance solutions for insurance brokers, agents, and carriers. Following these announcements, the company's shares moved 0.14%, and are now trading at a price of $58.29. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS